Author

Solenn Fabien

Observed names: Fabien, Solenn, S. Fabien, SOLENN FABIEN

Institution: Vifor Pharma (Switzerland)

Observed institutions: University of Geneva, University of Basel, Vifor Pharma (Switzerland), University Children’s Hospital Basel

ORCID: 0000-0003-4880-7105

Observed ORCID: 0000-0003-4880-7105

OpenAlex ID: A5038095680

Implementation of Motor Function Measure score percentile curves - Predicting motor function loss in Duchenne muscular dystrophy

2021 · Patricia Hafner, Simone Schmidt, et al. · European Journal of Paediatric Neurology · 19

Management of Patients with Heart Failure at High Risk of Hyperkalaemia: The CARE-HK in HF Registry

2025 · Stephen J. Greene, Andrew J. Sauer, et al. · European Journal of Heart Failure · 6

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry

2024 · STEPHEN J. GREENE, MICHAEL BÖHM, et al. · Journal of Cardiac Failure · 5

Smartwatches in the Assessment of Heart Failure Patients in Epidemiology and Pathophysiology Studies: A Scoping Review

2025 · Solenn Fabien, Sandra Waechter, et al. · ESC Heart Failure · 4

Comparative analysis of randomized versus real-world populations in heart failure: DIAMOND trial vs CARE-HK registry

2026 · Solenn Fabien, Francesco Fioretti, et al. · ESC Heart Failure

Dmd Clinical and Biomarkers

2019 · O. Dorchies, L. Neff, et al. · Neuromuscular Disorders

Works count: 7

Citation count: 34

H-index: 4

I10-index: 1